• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory

    Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies

    Waters Corp. Acquires Light Scattering Company Wyatt Technology
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    Peptide Aggregation - A Complex Topic

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Traceability & 2D Barcodes

    Complex in Complex – New Hopes for Better Drug Delivery in Topical Dosage Formulation

    Proactive Resource Group Offers DSCSA Services for Pharma Companies

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Manufacturing Complex Peptide APIs

    How CDMOs Can Leverage Contract Terms to Facilitate Payment

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility

    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA

    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Purification – A Bottleneck for Large-Scale Manufacturing of Oligonucleotide API?

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene International Ltd.

    CMC Pharmaceuticals

    U.S. Pharmacopeia (USP)

    INCOG BioPharma Services

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene International Ltd.

    CMC Pharmaceuticals

    U.S. Pharmacopeia (USP)

    INCOG BioPharma Services

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Expansion Trends: Trading Places

    Who�s expanding via asset-transfer deals?

    Gil Roth11.09.10

    Expansion Trends: Trading Places

     

    Who’s expanding via asset-transfer deals?

     

    By Gil Roth

    Contract Pharma

     

    Asset-transfer deals — buying a pharma company’s facility for pennies on the dollar, typically with a trailing supply agreement — are a mainstay in our industry. Many contract service providers began operations through such arrangements, with a management buyout of a facility otherwise slated for shutdown.


    Since the beginning of the global financial crisis, we’ve seen a number of dosage form facility acquisitions by CMOs since the beginning of the global financial crisis: Halo Pharma/ Abbott, Corden Pharma/BMS, Corden/AZ, Unither/Sanofi-Aventis (twice!), among others.


    One industry expert told me that he could name at least 20 solid dosage facilities up for sale with a supply agreement right now, as well as half-a-dozen parenteral sites and ‘10 or more’ biologics-based ones. At the same time, I often receive e-mails from equipment resellers, offering never-used top-of-the-line lab and manufacturing equipment they picked up from major pharma companies.


    On the API side, of course, the numbers are even more daunting. I heard that one of the majors had a booth at CPhI/ICSE devoted solely to its inventory of API facilities. And a few days before I began writing this article, I received an e-mail solicitation to bid on another company’s API facility in central Canada. (I admit, I was tempted for a moment or two.)


    With major pharma companies working to reduce fixed costs, and mega-mergers providing cover for a wave of network rationalizations, are CMOs and CROs going to take the bait and buy up some underutilized assets? Will we see sites spun out as new contract manufacturers? Will providers use discrete assets to bridge gaps in their business models? Will these deals be business as usual, or are new partnership models emerging?


    Or will supply agreements lapse too soon and leave providers with too much overhead from underperforming assets? If you’re a long-time reader, then you know my ambivalence about inorganic growth strategies. At heart, I’m a believer in slow and steady growth, so I’d be very cautious about a proposed “can’t-miss” facility carve-out. I’ve also never run a significant business, so I haven’t had to address the temptations of such an offer.

     

    Continental Divide


    So in our crisis = opportunity world, who’s buying in? Many of these transfer-deals have taken place in Europe, where labor laws and work councils give companies an incentive to find a buyer, rather than shut a plant down. In a DCAT presentation several years ago, Bill Wiederseim of PharmaBioSource, a consulting firm that helps broker facility transactions, contended that closing a European pharma facility costs approximately $1 million per employee. Given that “incentive,” many deals in Europe are structured to keep employees employed.


    Recipharm, a privately owned CMO based in Sweden, made news in October when it acquired from Abbott a former Solvay contract manufacturing site in Parets, Spain. The purchase was Recipharm’s seventh since 2007 and third in the past year (not all were classic asset-transfers), following Cobra Biologics and Hospira’s large-scale lyo-site in Wasserburg, Germany.


    I spoke with Mark Quick, Recipharm’s executive vice president of Corporate Development, about the company’s strategy of buying up pharma assets. “We have an acquisition-led growth structure, no doubt,” said Mr. Quick. “We invest in the development side of the business, with the intent of getting clients in the early stage, and moving along to commercial. When it comes to our acquisition strategy, a site has to offer us at least one of three things we didn’t previously have: a significant relationship with a client, a geographic presence, or a new technology.”


    He noted that the Abbott/Solvay site in Parets — which makes solid dosage, ointments and oral liquids — brought with it a number of existing customer relationships. I asked if there were concerns about losing those clients after the change in management. “Not really,” he said, “because it’s not a change in management. Part of our due diligence is determining whether the management team should remain there.”


    He stressed that the company doesn’t try to Lean its facilities into a tightly-focused network, preferring to treat sites as separate P&Ls centers, in order to foster entrepreneurialism. “We integrate the back office for some sites, but our guidance is in terms of policies, not trying to weed out costs. We don’t see the benefits to a work environment of our coming in and trashing the computer systems and the like to get everything onto a corporate standard. Our business development is integrated, but we carry low corporate overhead otherwise.”


    As far as Recipharm’s other acquisition criteria go, Mr. Quick noted that the company is looking to establish a foothold in America, and that it has no presence in cytotoxics. Yet.

     

    Dance with Who Brung Ya


    From the 1990s through 2004, Patheon bought a number of former pharma sites, adding operations from Upjohn, Roche, Hoechst Marion Roussel, Novartis, and Aventis (and I’m probably missing one or two). I covered their internal growth initiatives in our previous issue, but it seems that they’re also lured by some of the assets that are shaking out of large pharma networks.


    Said Geoffrey Glass, Patheon’s executive vice president of Global Strategy, Sales, and Marketing, “Patheon is actively

    pursuing strategic customer deals, including asset acquisitions, in both the Development Services and Commercial Manufacturing areas. Crafting these large-scale asset transactions so that one party isn’t disadvantaged relative to the other requires the right set of circumstances and transparency by both parties. Having those factors at the same time can be hard to find, but it happens.”


    Mr. Glass added that we’ll likely see more asset-transfer pacts from pharma and biopharma in the short term, “but over time the market for such deals will hit a saturation point and the number of potential buyers will shrink dramatically.”

    IDO?


    Aptuit, another company built from a series of acquisitions, acquired GSK’s Medicines Research Centre in Verona, Italy this past July. The site and its 500-person staff are focused on drug discovery, lead optimization, API development and manufacturing, and preclinical/clinical drug development. GSK announced plans to close the site in February 2010, but conversations among current and former Glaxovians — including Aptuit’s chief executive officer Tim Tyson — led to a deal to shift the site to Aptuit.


    Colin Terry, Aptuit’s executive vice president, Commercial Operations, told me, “Now that we have Verona, we have a structure in place where we can take someone’s idea, and move them all the way from discovery to launch. We have what we call an integrated development organization, not a CMO nor a CRO.”


    The transaction includes a three-year transition agreement with GSK, said Mr. Terry, “in order to take Verona from a standalone cost center to a profitable business in its own right. GSK agreed with us that that should take around three years to accomplish. During that period, they’re not obliged but they have an interest in giving us some work that would be mutually beneficial.”


    Aptuit also managed to sell a minority stake in the facility to Siena Biotech, an Italian company working on a pipeline of Alzheimer’s disease, Huntington’s disease and oncology treatments. Aptuit became a preferred provider to Siena in the process. Mr. Terry noted that Siena’s chief executive officer, Giovanni Gaviraghi, was GSK’s former R&D director for Verona. “We were fortunate that both deals had a foundation in good relationships,” said Mr. Terry, who also previously worked at GSK.

     

    Spinning R&D


    GSK isn’t the only member of the New Pharma that has reduced its R&D efforts in recent years and spun off or shut down those sites. Many of the major players have pared down,focusing on certain therapeutic classes and moving out programs that could be better served elsewhere.


    Research-oriented sites are a different beast than manufacturing facilities, to be sure. For CMOs, a new facility generally represents a silo of services, not necessarily something that can be leveraged more broadly across service offerings. CROs, on the other hand, may find greater value in building scale and new capabilities through former pharma sites.


    In September, Covance built an “asset-transfer” deal with Sanofi-Aventis, in which Covance paid $25 million to take over a pair of sites in France and the UK, and Sanofi committed to guarantees of between $1.2 and $2.2 billion for tox, CMC and clinical trial services over the course of 10 years. Sanofi had slated the sites for closure in June 2009; Covance has committed to retaining employment at both sites for at least five years.


    Historically, Sanofi-Aventis hasn’t been a strong proponent of outsourcing, so the agreement with Covance raised eyebrows. Under new chief executive officer Chris Viehbacher, the company has looked to reduce its internal R&D efforts, and this pact shows they’re serious. Like every one of its major competitors, Sanofi has major revenue shortfalls ahead, and moves like this may not only help keep earnings up, but also accelerate R&D.


    Ken Getz, senior research fellow at Tufts Center for the Study of Drug Development (CSDD), said, “The third quarter of 2010 has seen an uptick in new sponsor-CRO alliance agreements, including the Covance/Sanofi-Aventis R&D partnership, and the GSK and BMS development partnerships with Parexel, PPD and ICON. All of these alliances reflect sponsor efforts to integrate their operations to better leverage outsourcing and to transfer underutilized infrastructure and noncore capabilities.”


    He added, “We expect to see more partnerships announced in the coming six to 12 months between sponsors and major CROs as pharmaceutical companies vie to manage rising project volume with increasingly limited resources post industry consolidation.”


    John Watson, Covance’s corporate vice president and president - Strategic Partnering & Integrated Drug Development, discussed the Sanofi transaction with me, explaining, “These two sites bring a couple of key capabilities to us: 1) CMC, which we’ve been looking at for a long time. Covance has no desire to be in Phase III or commercial manufacture, but a very good presence in integrating drug development and program management, to move from lead optimization to preclinical to proof of concept, and 2) Radiolabelled synthesis: We’re the largest provider of ADME studies in Phase I units. We used to outsource this part, and now we have it in-house.” He noted that the geographic location of the site was important,from a growth perspective, as some biotechs in France prefer to work with companies in France.

     

    Lilly of the Greenfield


    One industry figure involved in facility sales remarked to me, “Lilly stands alone in this field. They’ve probably done more than anybody, when it comes to finding a way to monetize an R&D asset.”


    Lilly has been at the center of three significant asset-transfer deals: Covance took over its Greenfield, IN central lab in August 2008, Evonik acquired its Tippecanoe API site in October 2009, and Fisher Clinical Services took over CTM supplychain responsibilities — and a Lilly site on its main campus — in March 2010. The transactions included supply agreements (or their analog) of 10 years, nine years and five years, respectively. For more on the Fisher transaction, and its “insourcing” model (no outside clients will be brought into their Lilly CTM building), see my Newsmakers interview with the two companies in our May 2010 issue.


    Judy Kay Moore, a spokesperson for Lilly, told me, “Our partnerships with Covance, Thermo Fisher Scientific and others are designed to improve productivity in R&D and exemplify how Lilly is transforming the ways it does business in order to drive down the cost of drug development. These strategic partnerships increase our flexibility and agility, and give us much greater access to ideas, expertise and resources that will help us bring a contiguous flow of innovative new medicines to patients.”


    Mr. Watson at Covance remarked, “When our Lilly partnership was announced, it was like a shot heard ‘round the world.” He said that some considered it a symptom of “what was wrong” at Lilly, but two years later they’re looking at the arrangement more seriously and trying to figure out how to build something comparable.


    He noted that Covance has more than 50 clients conducting work at the Greenfield facility today. “We inherited 260 Lilly employees in 2008, and we’re over 400 now,” he said. At its peak, the site once employed more than 1,200 Lilly staffers. “So we have room to grow.”

     

    The Big Picture


    It remains to be seen how well Lilly’s competitors will strike the balance between cost and productivity. Pfizer, in the midst of shrinking its network after the Wyeth acquisition of 2009, announced plans in May 2010 to shut down operations at eight manufacturing sites in Ireland, Puerto Rico and the U.S. by the end of 2015, with additional plans to reduce operations atsix other plants in Germany, Ireland, PR, the UK, and the U.S. A visit to the website of PricewaterhouseCoopers (http:// www.pwc.co.uk/eng/issues/corporate_finance_pfizer.html) showed a half-dozen Pfizer sites for sale, running the gamut from oral solid dosage to state-of-the-art biologics, but not all of them with supply agreements.


    I asked Tony Maddaluna, senior vice president, Strategy and Supply Network Transformation for Pfizer Global Manufacturing (PGM), which dosage forms or geographies may be more appealing to CMOs than others, in terms of facility carve-outs. He replied, “The success of a site sale is largely dependent upon the right balance in the value proposition between the buyer’s business needs and the particular capabilities of the site being offered.If the buyer can leverage these capabilities and grow its business, it is a win-win for everyone, especially our colleagues.”


    Mr. Maddaluna added, “The economy has not impacted Pfizer’s extensive, thorough and well-established site exit process. This process supports our plant network strategy and advances its end goal — to be a globally competitive make-or-buy network.In other words, how do we optimize our supply network to be competitive, innovative and flexible enough to respond to emerging cost pressures and other industry shifts?Maintaining our competitive advantage — which is as much about quality and security of supply as it is about cost — is essential moving forward.”

     

    We’re Practically Giving It Away!


    As large pharma continues to devolve its infrastructure, we’re sure to see more assets up for grabs, in both manufacturing and R&D. It remains to be seen whether these transactions will tend more toward innovative partnering efforts between sponsors and providers, or conventional capacity/geography plays.


    Or, to quote one industry expert, “There’s not a lot of bandwidth on the provider side to take in all these facilities. In some instances, owners are going to have to make some fairly brutal decisions and shut sites down for the good of the industry. Selling a facility on the cheap so that it’s limping along doesn’t help anyone. It just leads to the new owners selling services cheap to fill capacity, and that’s damaging to the overall health of the industry. We need large pharma to be realistic about the facilities that are worthwhile assets, and we need providers to understand when a deal really is too good to be true.”

    Gil Y. Roth has been the editor of Contract Pharma since its debut in 1999. He can be reached at gil@rodpub.com


     

    Related Searches
    • Solid Dosage
    • Manufacturing
    • contract pharma
    • pharma companies
    Suggested For You
    Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss
    Pfizer Revenues Soar to Record-Breaking $100B in 2022 Pfizer Revenues Soar to Record-Breaking $100B in 2022
    Lilly to Invest $450M at Manufacturing Site in Research Triangle Park Lilly to Invest $450M at Manufacturing Site in Research Triangle Park
    CuriRx Launches CuriLytics Platform for Biotherapeutic Development CuriRx Launches CuriLytics Platform for Biotherapeutic Development
    Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer
    Asychem Partners with LaNova Medicines Asychem Partners with LaNova Medicines
    Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership Emergent BioSolutions, Providence Therapeutics Enter Vaccine Manufacturing Partnership
    Tekni-Plex Names Chris Qualters as CEO of Healthcare Division Tekni-Plex Names Chris Qualters as CEO of Healthcare Division
    COVID Booster Vaccines: What’s Next for FDA COVID Booster Vaccines: What’s Next for FDA
    Eloxx Pharmaceutical Appoints Ali Hairiri as Chief Medical Officer Eloxx Pharmaceutical Appoints Ali Hairiri as Chief Medical Officer
    Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration Boehringer Ingelheim, Twist Bioscience Enter Antibody Discovery Collaboration
    The Future of Clinical Trials The Future of Clinical Trials
    API Development Trends API Development Trends
    Spray Drying: A Proven Approach to Enhance the Solubility of APIs Spray Drying: A Proven Approach to Enhance the Solubility of APIs
    Outsourcing the Manufacture of Clinical Trial APIs Outsourcing the Manufacture of Clinical Trial APIs

    Related Breaking News

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Industry News
      Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss

      Andelyn Biosciences, Odylia Therapeutics Partner to Manufacture Gene Therapy for Vision Loss

      Novel AAV capsid Anc80 enables efficient gene transfer.
      02.01.23

    • Breaking News | Financial Reports
      Pfizer Revenues Soar to Record-Breaking $100B in 2022

      Pfizer Revenues Soar to Record-Breaking $100B in 2022

      Comirnaty and Paxlovid rake in $56.7 billion in 2022 while sales of these COVID products are expected to decline as much as 60% in 2023.
      01.31.23

    • Breaking News | Facilities | Industry News
      Lilly to Invest $450M at Manufacturing Site in Research Triangle Park

      Lilly to Invest $450M at Manufacturing Site in Research Triangle Park

      Expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly's incretin products.
      01.30.23


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      CuriRx Launches CuriLytics Platform for Biotherapeutic Development

      To provide CMC analytical services to support complex biotherapeutic development using high resolution mass spectrometry.
      09.21.21

    • Breaking News | Promotions & Moves
      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Rentschler Biopharma Appoints Dr. Christian Schetter as Chief Scientific Officer

      Schetter has a proven track record across the entire biopharmaceutical value chain.
      09.20.21

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Astellas To Transfer Manufacturing Plant To Delpharm
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Traceability & 2D Barcodes
    • OLON Enters ADC Market
    Breaking News
    • AVROBIO Sells Cystinosis Gene Therapy for $87.5 Million
    • Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    • JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    • Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    • Cellular Origins Launches Robotic Platform for Scalable Manufacture of Advanced Therapies
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Verdure Sciences Receives Award for Sustainable, Ethical Turmeric Sourcing
    BGG Receives Patent for Saw Palmetto ID Method
    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Coatings World

    Latest Breaking News From Coatings World

    Boeing Starts Construction on New St. Louis Facility
    Brand Finance: Post-COVID Recovery Slows for Chemicals Industry Battling Energy Crisis
    BCF Calls for Greater Urgency on REACH Impasse
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CareDx, Miromatrix Collaborate on Bioengineered Organs Research
    Capitainer Releases to Market its Fully Automated Sample Handler
    Titan Medical Licenses Most IP to Intuitive; CEO Steps Down
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Meiji Seika Pharma, Adcock Ingram Pharma Complete Construction of New Manufacturing Facility
    JSR Life Sciences Consolidates KBI Biopharma and Selexis SA
    Charles River, Wheeler Bio Partner to Operate RightSource Laboratory
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Beautycounter Names New Interim CEO
    Shaz & Kiks Available at Sephora
    Stetson Introduces Men’s Grooming Portfolio
    Happi

    Latest Breaking News From Happi

    Shaz and Kiks Launches at Sephora
    Beautycounter Appoints Board Director Mindy Mackenzie Interim CEO
    Unilever Ventures’ Backs Selva Ventures in $34 Million Fund for Early-Stage CPG Brands
    Ink World

    Latest Breaking News From Ink World

    ACTEGA, Makro Labelling to Advance Signite Technology
    BCF Requests Greater Urgency on REACH Impasse
    Updated Method Published for Entire BASF Product Portfolio
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    ACTEGA teams with Makro Labelling to advance Signite technology
    Constantia Flexibles and SB Packagings commence joint venture
    Inland donates new VersaStudio printer to local high school
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mann+Hummel Names President Air Filtration Americas
    KNH Launches Eco-Friendly Menstrual Pads
    Niine Introduces India's First PLA-Based Sanitary Pads
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Enrollment Completed in Anika Therapeutics' Hyalofast Study
    Exactech Releases Next-Gen GPS Shoulder
    Data Shows Favorable Survivorship of MISHA Knee System & Reduction of Arthroplasty Risk in Patients
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    onsemi Presents Path to Accelerate Revenue Growth
    STMicroelectronics Introduces Waterproof MEMS Pressure Sensor
    Graphene Flagship to Join Euro Nano Forum 2023

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login